Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-114 (Vamotinib) in Resistant Ph+ CML
NCT02885766Phase 2Unknown
- Sponsor
- Fusion Pharmaceuticals Inc.
- Start
- Jul 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vamotinib in chronic myeloid leukemia (CML), sponsored by Fusion Pharmaceuticals Inc. Primary endpoints: Dose Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
vamotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02885766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885766.